Abstract
The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Current Drug Targets
Title: Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design
Volume: 8 Issue: 3
Author(s): R. G. Ducati, L. A. Basso and D. S. Santos
Affiliation:
Keywords: 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, shikimate 5-dehydrogenase, shikimate kinase, 5-enolpyruvylshikimate-3-phosphate synthase, chorismate synthase, antimycobacterial drug design
Abstract: The aetiological agent of tuberculosis (TB), Mycobacterium tuberculosis, is responsible for millions of deaths annually. The increasing prevalence of the disease, the emergence of multidrug-resistant strains, and the devastating effect of human immunodeficiency virus co-infection have led to an urgent need for the development of new and more efficient antimycobacterial drugs. Since the shikimate pathway is present and essential in algae, higher plants, bacteria, and fungi, but absent from mammals, the gene products of the common pathway might represent attractive targets for the development of new antimycobacterial agents. In this review we describe studies on shikimate pathway enzymes, including enzyme kinetics and structural data. We have focused on mycobacterial shikimate pathway enzymes as potential targets for the development of new anti-TB agents.
Export Options
About this article
Cite this article as:
Ducati G. R., Basso A. L. and Santos S. D., Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design, Current Drug Targets 2007; 8 (3) . https://dx.doi.org/10.2174/138945007780059004
DOI https://dx.doi.org/10.2174/138945007780059004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA New Perspectives on Machine Learning in Drug Discovery
Current Medicinal Chemistry Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Editorial (Thematic Issue: Small Molecule Drug Discovery for Pediatric Diseases)
Mini-Reviews in Medicinal Chemistry Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Development and Validation of a Liquid Chromatographic Method for Aroylhydrazones at Hydrolytic Conditions
Current Pharmaceutical Analysis Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Graphical Abstracts
Letters in Organic Chemistry MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Biographical Sketches of Authors
Current Topics in Medicinal Chemistry Assessing the Performance of 3D Pharmacophore Models in Virtual Screening: How Good are They?
Current Topics in Medicinal Chemistry Recent Patents on DNA Sequences and Diagnostic Methods for the Identification and Strain Differentiation of Mycobacterium Tuberculosis
Recent Patents on DNA & Gene Sequences Synthesis and Biological Evaluation of Novel N' (4-aryloxybenzylidene)- 1H-Benzimidazole-2 Carbohydrazide Derivatives as Anti-Tubercular Agents
Combinatorial Chemistry & High Throughput Screening Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design New Insights into Lipidic Secondary Metabolites in Mycobacteria
Current Chemical Biology Application of Sugar-Base Anhydro Bridge for Modification of Nucleosides in the 2’- and/or 3’-Positions - Revisited
Current Organic Chemistry